Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Charter Communications Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Charter Communications Inc trades at $131.19 (market cap $16.08B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.5× Charter Communications Inc's market cap. Which is the better fit depends on your goals.
| ALNY | CHTR | |
|---|---|---|
Market Cap | $39.89B | $16.08B |
Sector | Health | Media |
52-Week High | $491.22 | $399.61 |
52-Week Low | $278.09 | $125.54 |
Enterprise Value | $38.15B | $112.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Charter Communications (CHTR) trades at $130.73, down 2.69% today, with a bearish technical signal and oversold short-term RSI. The stock shows extremely low valuation multiples (P/E 3.54, P/S 0.32) against solid profitability (ROE 30.23%, net margin 9.03%), while recent news highlights potential partnerships with SpaceX and acquisition interest from Comcast. Cash flow remains positive despite high capital expenditures, though revenue growth has stagnated near $54.8B annually.
CHTR presents a deep value opportunity with significant upside to the $204.67 consensus target, but high debt ($93.21B long-term) and competitive pressures in broadband/video markets pose risks. Investor sentiment is mixed amid earnings misses, yet analyst coverage leans bullish with 47% buy ratings. The stock's trajectory hinges on operational execution and strategic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
